Markers of Inflammation in Relation to Long-term Cardiovascular Mortality in Patients with Lower-extremity Peripheral Arterial Disease
Overview
Authors
Affiliations
Background: Elevated levels of inflammatory mediators reflect vascular inflammation, and play a significant role in the genesis of atherosclerosis, plaque instability and rupture.
Methods And Material: Plasma α-defensin and serum high sensitivity C reactive protein (hs-CRP) levels were examined in 463 patients with lower-extremity peripheral arterial disease (PAD). The relationships between inflammatory markers and lethal outcome were examined by Cox regression, and receiver operating characteristic (ROC) analysis.
Results: Overall, 126 patients died, hereof 59 of cardiovascular causes. The patients with chronic critical limb ischemia (CLI) at baseline had significantly higher α-defensin and hs-CRP levels compared with patients with intermittent claudication (IC). For patients with IC, the relative risk for cardiovascular mortality was three times higher in patients within the upper tertile of α-defensin concentration (>162 μg/l), when compared with those in the two lower tertiles (HR 3.04 95% CI 1.26-7.32). The multivariable model revealed that IC-patients with high α-defensin and high hs-CRP concentration had more than 5 times higher risk for cardiovascular mortality than those with either high α-defensin or high hs-CRP alone, and low α-defensin or low hs-CRP concentrations (HR 5.16, 95% CI 1.78-14.8). Area under the ROC curve for combined use of high values of α-defensin and hs-CRP was 0.71 (95% CI 0.57-0.85). The addition of α-defensin or hs-CRP to conventional risk factors significantly improved the accuracy of risk prediction model for cardiovascular mortality. No associations were found among α-defensin, hs-CRP, and lethal outcome for patients with CLI.
Conclusions: Combined analysis of α-defensin and hs-CRP, adds prognostic information with regard to the long-term cardiovascular prognosis among patients with IC.
Shapira M, Roguin A, Fayad I, Medlij L, Khateeb A, Egbaria D Int J Cardiol Heart Vasc. 2024; 53:101465.
PMID: 39091435 PMC: 11292519. DOI: 10.1016/j.ijcha.2024.101465.
Cardiovascular Prognosis in Patients with Peripheral Artery Disease and Approach to Therapy.
Curcio A, Panarello A, Spaccarotella C, Indolfi C Biomedicines. 2023; 11(12).
PMID: 38137352 PMC: 10740501. DOI: 10.3390/biomedicines11123131.
Wang X, Nai Y, Gan J, Lian C, Ryan F, Tan F Int J Mol Sci. 2023; 24(13).
PMID: 37446302 PMC: 10342137. DOI: 10.3390/ijms241311123.
Circulating Biomarkers in Lower Extremity Artery Disease.
Ziegler L, Hedin U, Gottsater A Eur Cardiol. 2022; 17:e09.
PMID: 35401792 PMC: 8978021. DOI: 10.15420/ecr.2021.58.
The Role of Circulating Biomarkers in Peripheral Arterial Disease.
Saenz-Pipaon G, Martinez-Aguilar E, Orbe J, Miqueo A, Fernandez-Alonso L, Paramo J Int J Mol Sci. 2021; 22(7).
PMID: 33808453 PMC: 8036489. DOI: 10.3390/ijms22073601.